Abstract
Diabetes mellitus is the leading cause of end stage renal disease. Cystatin C, a marker of early renal impairment has been shown to be associated with diabetes. However, it is not clear if cystatin C is associated with prediabetes, an early stage in the hyperglycemic continuum where prevention efforts have been shown to be effective in delaying or preventing the onset of diabetes. We examined 2,033 participants from the National Health and Nutrition Examination Survey 1999–2002, aged ≥20 years (female 47.2 %) who were free of diabetes mellitus, chronic kidney disease and with body mass index <30 kg/m2. Prediabetes (n = 541) was defined as a 2-h glucose concentration of 140–199 mg/dL, or a fasting glucose concentration of 110–125 mg/dL, or an A1C value of 5.7–6.4 %. Cystatin C levels were categorized into gender-specific quartiles for analysis. Elevated levels of serum cystatin C were associated with prediabetes after adjusting for potential confounders including serum total cholesterol, systolic blood pressure, body mass index and C-reactive protein. Compared to those with cystatin C in the lowest quartile, the multivariable odds ratio (95 % confidence interval) of prediabetes among those in the highest quartile was 2.08 (1.09–3.97), p for trend = 0.02. Although, this association was stronger among women and non-Hispanic whites, there was no significant interaction by sex (p = 0.1) or by race-ethnicity (p = 0.6). Our findings suggest that elevated levels of serum cystatin C are associated with prediabetes in a nationally representative sample of non-obese US adults.
Similar content being viewed by others
References
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436–40.
Mussap M, Dalla VM, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.
Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34.
Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.
Willems D, Wolff F, Mekahli F, Gillet C. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;42:108–10.
Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335–40.
American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33 Suppl 1:S11–61.
Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.
Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007;30:1724–9.
Lafarge JC, Naour N, Clement K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580–6.
Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol. 2008;3:1786–91.
Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich). 2011;13:925–30.
National Center for Health Statistics. The National Health and Nutrition Examination Survey 1999–2000: Survey Operations Manuals, Brochures, Consent Documents. Available at: http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/current_nhanes99_00.htm
National Center for Health Statistics. The National Health and Nutrition Examination Survey 2001–2002: Survey Operations Manuals, Brochures, Consent Documents. Available at: http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/current_nhanes_01_02.htm
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1:S62–9.
Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43:1016–22.
Newman DJ. Cystatin C. Ann Clin Biochem. 2002;39:89–104.
National Center for Health Statistics. Laboratory procedures used for NHANES 1999–2000. Available at: http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/lab99_00.htm (2008). Accessed 25 Feb 2011.
National Center for Health Statistics. Laboratory procedures used for NHANES 2001–2002. Available at: http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/lab01_02.htm (2008). Accessed 25 Feb 2011.
Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis. 2007;50:918–26.
Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37:389–95.
Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens. 2006;15:270–5.
Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354–60.
Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45:535–40.
Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol. 1999;52:363–70.
Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard BC. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426–32.
Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59:241–6.
Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118:1416.
Leung-Tack J, Tavera C, Martinez J, Colle A. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14:247–58.
Reffelmann T, Krebs A, Ittermann T, et al. Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis. 2010;211:660–6.
Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care. 2007;30:354–9.
Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care. 2007;30:854–60.
Acknowledgments
NIH/NIEHS grants 1 R01 ES021825-01 and 5 R03ES018888-02 (AS) and Singapore Ministry of Health’s National Medical Research Council under its Talent Development Scheme R927/36/2012 (CS).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sabanayagam, C., Wong, T.Y., Xiao, J. et al. Serum cystatin C and prediabetes in non-obese US adults. Eur J Epidemiol 28, 311–316 (2013). https://doi.org/10.1007/s10654-013-9781-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-013-9781-3